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Summary 19 
Background: Acinetobacter baumannii are problematic hospital pathogens, and the 20 
increased incidence of multi drug resistance has significantly limited treatment options. The 21 
global epidemiology is not fully characterised due to large data gaps from low- and middle-22 
income countries. This study characterised the molecular epidemiology of an A. baumanniii 23 
outbreak in Egypt.  24 
Methods: Fifty-four A. baumannii isolates were recovered from a 4-month-outbreak at Tanta 25 
University Hospitals (TUH). Associated clinical and demographic data, and the antibiogram 26 
were analysed, and carbapenem resistant isolates were screened for acquired carbapenemase 27 
genes by PCR and sequencing. Epidemiological typing was performed by single-locus 28 
sequencing of blaOXA-51-like and Multi Locus Sequence Typing (MLST), and sequence types 29 
(STs) were analysed based on maximum-likelihood phylogeny (PhyML) to identify 30 
relatedness. 31 
Findings: Immune suppression and ICU admission were the most common co-morbidity and 32 
risk factor. Carbapenem resistance accounted for 81%, and correlated with the presence of 33 
OXA-23, NDM-1 and -2, and VIM-1 and -2 carbapenemases. Nine different blaOXA-51-like 34 
genes were identified which corresponded to 22 different Sequence Types (STs), including 35 
10 novel. International clone (IC2) was the predominant clone. PhyML analysis revealed the 36 
presence of 2 distinct clones with multiple sub-lineages.  37 
Conclusion: Given the short duration of the study, there was a rare heterogeneous population 38 
in the hospital. Carbapenem resistance is mediated by acquired carbapenemases in diverse 39 
lineages indicating the possibility of horizontal gene transfer. The diversity indicates the 40 
influx of multiple lineages of IC2 into TUH from unknown sources.  Molecular 41 
epidemiological studies are essential for infection prevention and control measures.  42 
 43 
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Introduction 44 
Acinetobacter baumannii is an important globally distributed hospital-acquired Gram 45 
negative pathogen with a propensity to cause outbreaks, particularly in the intensive care 46 
patient population. Common infections with A. baumannii include ventilator-associated 47 
pneumoniae (VAP), sepsis, urinary tract infections (UTI), and skin and soft-tissue infections 48 
(SSTI) [1]. A. baumannii is a clonal pathogen in nature, and there are at least eight 49 
international (IC) clones that contribute to the global dissemination of multidrug resistant 50 
(MDR) A. baumannii [2]. The prevalence of MDR  A. baumannii in hospitals has put the 51 
organism on the ‘ESKAPE’ pathogens list: an acronym developed by the Infectious Diseases 52 
Society of America (IDSA) for a group of common life-threatening nosocomial pathogens 53 
that escape the effects of antimicrobial drugs, and includes Enterococcus faecium, 54 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 55 
aeruginosa and Enterobacter spp. [3]. Carbapenem resistance is rising significantly in Gram-56 
negative pathogens, and in A. baumannii is frequently attributed to the presence of acquired 57 
carbapenemases within mobile genetic structures such as integrons, transposons and plasmids 58 
[4]. β-lactamases are classified as Class A-D according to the Ambler scheme and of 59 
particular importance in carbapenem resistant A. baumannii are the class D Oxacillinases: 60 
either the acquired OXA-23-like, -40-like, -58-like, -143-like, -235-like or the intrinsic OXA-61 
51-like-family. Less frequently found are class B metallo-β-lactamases IMP, VIM and NDM, 62 
and class C KPC enzymes. Carbapenem resistance mediated by these enzymes has been a 63 
major factor in the successful dissemination of A. baumannii clones globally.  64 
Different typing methods have been used over the years on A. baumannii including, but not 65 
limited to, multi-locus sequence typing (MLST), Pulsed-Field Gel Electrophoresis (PFGE), 66 
and single-locus typing of the intrinsic blaOXA-51-like gene. Each typing method provides a 67 
different discriminatory level of typing and has its advantages and limitations. Two MLST 68 
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schemes (Oxford and Pasteur) define sequence types (STs) and clonal complexes (CC), 69 
suitable for population-based studies (6,7). The Oxford scheme is more discriminant in 70 
strains of short evolutionary distances, but some of the genes are affected by homologous 71 
recombination and/or insertion sequences disrupting the gene[7]. In the Pasteur scheme the 72 
genes are less affected by homologous recombination, however it seems less discriminant 73 
than the Oxford scheme. Nevertheless, both schemes are accepted, and listed on the 74 
pubMLST database. Single-locus sequencing of the blaOXA-51-like family of genes provides a 75 
simple and inexpensive method to identify major epidemic clones [8,9]. Initially believed to 76 
be species-specific to A. baumannii and used solely for identification and typing, the blaOXA-77 
51-like family has been found in other non-baumannii Acinetobacter, and therefore cannot be 78 
used as a sole method for identification and typing of A. baumannii [10].   79 
Several reports from the Middle East have indicated a high burden of MDR A. baumannii in 80 
hospitals, and a large heterogeneity of clones circulating [11–14]. Various carbapenemases 81 
such as OXA-23, OXA-58, OXA-40, VIM, and IMP  enzymes have been reported in A. 82 
baumannii from the Middle East Region[12,13,15,16]. In Egypt specifically, NDM-1 & -2 83 
are endemic enzymes in both A. baumannii as well as Enterobacteriaceae: particularly E. coli  84 
and Klebsiella [17,18]. Carbapenem resistance is exceptionally high in Egypt as well as in 85 
other countries in the region, where an increasing numbers of untreatable infections and local 86 
outbreaks have been documented[11,12]. Increased globalisation, medical tourism and travel 87 
have contributed to the subsequent global spread of these resistant organisms making this a 88 
cause for international concern. In the Middle East and North Africa, it appears that A. 89 
baumannii clinical outbreaks are usually poly-clonal, heterogeneous and MDR with endemic 90 
carbapenemases such as OXA-23 and NDM[12,19]. The endemicity of high level 91 
heterogenous MDR A. baumannii in the Middle East and North Africa requires studies on the 92 
local epidemiology of the pathogen in the region to understand the global dissemination of A. 93 
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baumannii. The aim of this study was to characterise the molecular epidemiology of clinical 94 
isolates of A. baumanniii from an outbreak in Tanta University Hospitals in Egypt in 2015.  95 
 96 
Materials and Methods 97 
Setting and design of the study. This is an outbreak investigation study. The isolates were 98 
collected from Tanta University Hospital (TUH), which is a 300-bed-tertiary referral hospital 99 
in Tanta, Egypt.  The A. baumannii isolates were collected from in-patients admitted to the 100 
hospital between March-June 2015. Upon identification of a sample as A. baumannii by the 101 
clinical microbiology laboratory (described below), an infectious diseases specialist reviewed 102 
the patients’ medical records and the collected parameters including: age, sex, date of hospital 103 
admission, location of patient, co-morbidities, type of culture, mode of acquisition of infection, 104 
recurrent Gram-negative infections, antibiotics prescribed, the outcome, and the antibiogram. 105 
Infection was labelled as nosocomial if patient developed clinical signs ≥48 hours after 106 
admission to the hospital[20]. Fifty-four clinical isolates were characterised in the outbreak, in 107 
addition to 9 environmental isolates from the ICU (ventilators, beds, and wall, floor and 108 
healthcare staff swabs) were also included in the study to investigate the dissemination of 109 
clones within the ICU. Informed written consent of the patients participating in this study was 110 
obtained. The Ethics Committee of Tanta University Hospital [TUMU/210/03.08.12] approved 111 
the experimental protocols. 112 
Bacterial isolates and antimicrobial susceptibility testing 113 
Seventy-four non-repetitive isolates of Acinetobacter baumannii-calcoaceticus complex 114 
identified using traditional phenotypic methods, API 20-NE (bioMérieux, France), and 115 
MALDI-TOF (Bruker-Daltonics, Germany) at TUH. The Clinical and Laboratory Standard 116 
Institute (CLSI) guidelines were used for the antimicrobial susceptibility by single-disc 117 
diffusion method, and Minimum Inhibitory Concentration (MIC) was determined for 118 
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imipenem and meropenem by broth dilution methods [21]. Escherichia coli NCTC 10418, 119 
and Pseudomonas aeruginosa NCTC 10662 represented the quality control strains used in the 120 
present study. To confirm the A. baumannii species identity, the gyrB multiplex method was 121 
used in addition to the amplification and sequencing of the blaOXA-51-like gene [22,23]. Only 122 
isolates confirmed as A. baumannii were included for further analysis (n=54).  123 
All carbapenem resistant isolates were screened for the presence of the acquired blaOXA-23, -58, 124 
-40, -143 and -235 carbapenemase genes by PCR as previously described [24], and blaNDM, -VIM, and –125 
IMP by PCR and sequencing[17,25]. The presence of Insertion Elements (ISAba1and 126 
ISAba125 upstream of blaOXA-23 and blaNDM, respectively was also done by PCR. All primer 127 
sequences and combinations are listed in Supplementary Table S1.  128 
Epidemiological typing  129 
In addition to single-locus sequencing of the intrinsic blaOXA-51-like gene, multi-locus sequence 130 
typing (MLST) was performed on all A. baumannii isolates using the Oxford scheme 131 
(http://pubmlst.org/abaumannii/) [5]. Novel sequence types (STs) were submitted to the A. 132 
baumannii MLST Database 133 
http://pubmlst.org/perl/bigsdb/bigsdb.pl?db=pubmlst_abaumannii_oxford_seqdef. A 134 
concatenated alignment with maximum likelihood phylogeny (PhyML) was constructed 135 
using Seaview to determine relatedness of isolates in the outbreak [26,27]. 136 
Statistical analysis. The analyses of data was done using an appropriate statistical software 137 
(SPSS, version 17, USA). Two-tailed T test was used to determine the significance of the data 138 
(p value ˂ 0.05). According to the survival status, patients were divided into two categories on 139 
day 15 from the first positive culture. Predictors of death were identified using Logistic 140 
regression analysis. In univariate analysis, all parameters with values ˂ 0.1 were considered. 141 
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 142 
Results 143 
Patient clinical data and bacterial isolates 144 
Fifty-four isolates (45 clinical samples from patients and 9 environmental samples) were 145 
confirmed to be A. baumannii by the gyrB multiplex method and sequencing of blaOXA-51-like. 146 
The remaining 20 isolates were identified as A. pittii (previously known as Genomic Species 147 
3). The A. baumannii isolates were all from adult patients ranging from 22-66 years old, with 148 
the average age of 44. Table I summarises the patients’ demographical and clinical data 149 
including co-morbidities. Immune suppression was the most commonly identified co-150 
morbidity (31%). Forty-three isolates (95%) were considered nosocomial, one isolates was 151 
considered community acquired, and the remaining isolate was from a patient transferred 152 
from another healthcare facility. Six patients had a history of hospitalisation within the last 30 153 
days before the A. baumannii infection due to their underlying co-morbidities.  Four of these 154 
patients had underlying liver disease, one had a haematological malignancy and one had 155 
diabetes. Thirty-nine isolates (87%) were from bronchoalveolar lavage (BAL) and sputum 156 
samples from patients with respiratory infections, three isolates from pus samples, one blood 157 
culture from a post-operative infection, and two were isolated from urine from patients with 158 
renal disease (Table I). Thirty-five isolates (77.8%) were from ICU patients and nine 159 
additional samples came from the ICU environment including swabs from ventilators, beds, 160 
the floor, walls and the hands of staff.  161 
   Predisposing factors associated with mortality: 162 
Table II presented the predisposing factors associated with death as well as the mortality rate 163 
among A. baumannii infected patients. It was found that the mortality percentage reached 164 
53.7 (29 patients). Regarding the univariate analysis, length of stay in ICU (p= 0.002), 165 
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Ventilator-associated pneumonia (p= 0.003), immunosuppression (p= 0.006), nosocomial 166 
mode of transmission (p= 0.01), solid malignancy (p= 0.05) were the most significant 167 
independent factors combined with high mortality percentages. Furthermore, the data of 168 
multivariate analyses revealed that significant predictors of death included; prolonged stay in 169 
ICU (Odd ratio: 3.96; 95% confidence interval: 0.85-7.36; p= 0.052), ventilator-associated 170 
pneumonia (OR: 2.85; 95%CI; 1.3-5.515; p= 0.017), immunosuppression OR: 1.95; 95%CI; 171 
1.02-3.3; p= 0.034), and previous A. baumannii infection (OR: 1.38; 95%CI; 1.25-2.11; p= 172 
0.043). Twenty-one patients (46.6%) had previous infections with a Gram-negative infection 173 
in the past 6 weeks prior to the current A. baumannii infection (Table II). 174 
Antimicrobial susceptibility 175 
All isolates were multi-drug resistant (MDR) (Supplementary material figure S2). All of 176 
isolates were resistant to ampicillin/sulbactam and nearly all were unsusceptible to 177 
ciprofloxacin (>80%). Carbapenem resistance accounted for 81% to imipenem and 178 
meropenem, and 100% to ertapenem in all isolates. Table S3 (in supplementary material)  179 
presents MIC ranges, MIC50 and MIC90 for the test carbapenems exhibiting the highest 180 
imipenem MIC50 and MIC90 (64 and 128 mg/L, respectively). This extremely high level of 181 
resistance was associated (p= 0.021) with the presence of acquired carbapanemases: OXA-23 182 
(n=45), NDM (n=17) and VIM-2 (n=4). Interestingly, six isolates co-harboured OXA-23 and 183 
NDM or VIM-2. Sixteen isolates harboured blaNDM-1 gene, and only one isolates harboured 184 
the blaNDM-2 gene. Three isolates harboured blaVIM-2, and only one from the ICU environment 185 
(ventilator 4) was blaVIM-1. ISAab1 was located upstream of all blaOXA-23 and ISAba125 was 186 
detected upstream of blaNDM. Figure 1 shows the presence of the acquired carbapenemases 187 
with the different clones in the hospital. All the ICU environmental samples showed similar a 188 
carbapenem resistance pattern (MIC ≥32mg/L) to the clinical isolates.  189 
Epidemiological typing  190 
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Single-locus sequencing of blaOXA-51-like is a useful preliminary typing method that can 191 
distinguish clones in a hospital setting, particularly to study local epidemiology [8]. However, 192 
it cannot be used as the sole typing method for A. baumannii due to the detection of blaOXA-51-193 
like genes in other non-baumannii species. We identified 9 different blaOXA-51-like variants: 194 
OXA-66, OXA-65, OXA-68, OXA-69, OXA-70, OXA-88, OXA-94, OXA-98, and OXA-195 
424 (table I). Further typing with MLST confirmed this diversity by identifying 22 different 196 
STs, including 10 novel ones: ST1289-1298. We were unable to obtain STs for some isolates 197 
(table I) due to the disruption of the gyrB and/or ghbB genes.  198 
The PhyML tree in figure 1 shows that there were 2 distinct lineages in the outbreak, with 199 
multiple sub-lineages, confirming the diversity of isolates. Within a single lineage, multiple 200 
sub-lineages of clonally-related isolates exist, for example as seen in ST-1289, -848, and -201 
1292 which appear to be clonally distinct from the other STs in the same lineage. 202 
Furthermore, isolates that appeared clonally related by being within the OXA-66 group, seem 203 
to have different STs, and forming distinct sub-lineages. As seen in figure 2, ST-455, -1293, -204 
1296, and -1114, form a distinct sub-lineage in comparison to ST-368, -1298, -195, and -205 
1295, although they are all in the OXA-66 group.  206 
Interestingly, given that this was an outbreak in a single hospital, there was no ‘endemic’ 207 
strain, and only a few recurring ST: ST-368, -1289, -1296, -1078, -231, -441 were identified 208 
in multiple isolates. This indicates the circulation of multiple strains simultaneously within 209 
the hospital.  210 
The isolates from the ICU environment (ST-1114, -231 and -1078) fall in two distinct 211 
lineages as seen in figure 2. Only ST231 and ST1078 have also been identified in patient 212 
isolates, whereas ST-1114 (from the ICU wall swab) did not appear in any clinical isolate, 213 
but is however clonally related to ST-455, -1293 and -1296 (figure 1). ST-231 (from the 214 
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healthcare worker’s hand swab) was found in 4 other clinical isolates demonstrating the role 215 
of healthcare workers in transmission of MDR organisms in the healthcare setting.  216 
Discussion 217 
The data presented in this work is based on 54 non-repetitive A. baumanii isolates from a 218 
hospital outbreak of A. baumannii over four months, and therefore the sample size is 219 
relatively small. However the data gives an indication of the local epidemiology of A. 220 
baumannii infections in Egyptian hospitals; and similar research studies conducted in Egypt 221 
previously have shown similar heterogeneity and high resistance rates [12,28,29].  222 
Typing by blaOXA-51-like single locus sequencing showed 9 heterogeneous groups, and this 223 
diversity was further confirmed by MLST which identified 22 different STs (Figure 1 and 224 
Table I). The majority of STs in the study correlated with International Clone (IC) 2 as and 225 
contained the most diverse STs which is concurrent with published data identifying IC2 226 
(OXA-66) as the most prevalent A. baumannii clone globally [30]. ST231 and ST441 are part 227 
of IC1 [30] and were recurring isolates in the outbreak suggesting the maintenance of IC1 228 
strains in the hospital. The less diversity seen in IC1 in TUH may be due to the success and 229 
ongoing adaptation of IC2 to the hospital environment globally, supported by the increasing 230 
prevalence, the diversity of STs in that clone, and its MDR phenotype[30,31] . The PhyML 231 
tree constructed on the concatenated STs in figure 1 revealed 2 distinct lineages in the 232 
outbreak, and a number of diverse sub-lineages of closely related isolates. This may indicate 233 
the influx of multiple diverse strains to TUH from the environment or other healthcare 234 
facilities.  235 
MLST and blaOXA-51-like single-locus sequencing are reliable, reproducible methods for 236 
investigating the clonal distribution of A. baumannii both locally as well as globally [32], and 237 
a correlation between blaOXA-51-like and IC clones has been previously described [8,9]. blaOXA-238 
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51-like sequencing is an easy and relatively cheap method suitable for preliminary screening, 239 
but should not be the sole method of epidemiological typing due to the limited 240 
discrimination, and the occurrence in non-baumannii species. MLST is more discriminatory 241 
but is more expensive and time consuming [8,9]. Having 2 schemes (Pasteur and Oxford) 242 
adds a level of confusion as to which is more appropriate to use in epidemiological studies. 243 
Each scheme has its advantages and limitations: Pasteur is less affected by homologous 244 
recombination, more appropriate for strain classification in clonal groups, but is less 245 
discriminant among closely related isolates, whereas Oxford works better for discrimination 246 
of STs among related clones and stains at short evolutionary distances, but is affected by 247 
homologous recombination and disruption of some of the loci in the scheme [7,30]. The 248 
reason for using the Oxford MLST scheme in this study is due to its higher discriminatory 249 
power in identifying more STs within clones, given that it was an outbreak in a single centre. 250 
This was followed by a PhyML to accurately determine the relatedness and diversity of the 251 
outbreak [26].  Each typing method has a level of discrimination, and although most of the 252 
time blaOXA-51-like typing or MLST can provide accurate data on epidemiology, although 253 
preliminary, these typing methods are relying on a specific number of genes which could be 254 
altered in recombination events, rather than the full genome of the pathogens. The use Whole 255 
Genome Sequencing (WGS) technology and typing using core-genome MLST (cgMLST) 256 
and will allow data from both typing methods to be easily extracted, but issues of cost and 257 
capacity need to be overcome before WGS can be part of routine clinical microbiology, 258 
especially in resource-limited countries [7,33,34].   259 
ICU admission, prolonged hospitalisation and underlying co-morbidities are the common risk 260 
factors for acquiring A. baumannii infections in hospital settings [35]. In the current study, 261 
77.8% of isolates were obtained from patients in the ICU with a respiratory focus of infection 262 
and associated with ventilation (Table I). ICU environmental isolates collected from the 263 
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ventilators, floor, walls and beds correlate with the patient isolates indicating probable cross-264 
infection, and the colonization of A. baumannii clones in the ICU environment. The clones 265 
present in the ICU belonged to ST1114 (IC2), ST231 (IC1) and ST1078 (table I and figure 1). 266 
In particular, ST1078 isolates were all associated with admission to ICU, and were cultured 267 
from the ventilators. The isolate from the healthcare hand swab was identified as ST231 268 
(IC1) isolate, thereby indicating the role of healthcare staff, not only the hospital 269 
environment, in potentially contributing to the transmission of A. baumannii by carrying the 270 
isolate asymptomatically.  271 
Our work presented high carbapenem resistance percentages (>80%), which might be 272 
attributed to the overuse as well as abuse of antibiotics by physicians. Both of blaOXA-23 and 273 
blaNDM-1 with ISAba1 and ISAba125 upstream, respectively, were the most common acquired 274 
carbapenemase genes found across different strains. Similar data have been reported from 275 
Egypt, North Africa and the Middle East where there appears to be a wide dissemination of 276 
OXA-23 and NDM-1 & -2 enzymes in different A. baumannii clones, highlighting the 277 
endemicity of these carbapenemases in the region(12,18,36). Although the study reports the 278 
dominance of blaOXA-23, there is a co-occurrence of blaOXA-23 and blaNDM, and blaOXA-23 and 279 
blaVIM carbapenemase genes in some strains. Preliminary work was done to characterise the 280 
localisation of the carbapenemases on plasmids, and 89.3% of isolates showed plasmid in their 281 
profiles, ranging from 2-169 kb in size (data not presented). Furthermore, class I and II integron 282 
structures were detected in the isolates, thereby indicating their association with transmission 283 
of resistance (data not presented). Future work is underway to investigate the genetic 284 
environments of the carbapenemase genes, and their potential localisation on transferrable 285 
plasmids. 286 
Mortality is commonly reported outcome in A. baumannii infected patients that can reach up 287 
to 30% [35]. In our current study, mortality reached >50%. Some risk factors that might 288 
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predispose for death among A. baumannii infected individuals which include; ventilator-289 
associated pneumonia, urinary tract infections, central venous catheter, prior antibiotic 290 
therapy and prolonged hospital stay [35]. These findings were in agreement with the results 291 
of the present work. Twenty-one patients had previous infections with a Gram-negative 292 
organism in the six weeks prior to the A. baumannii infection, and had consequently been 293 
treated with carbapenems (data not shown). Nine out of the 21 patients had a previous A. 294 
baumannii infection, which could indicate persistent or recurrent A. baumannii infections in 295 
the patients with co-morbidities. We do not have the previous A. baumannii isolates to 296 
confirm the above hypothesis, but it is also possible that patients acquired a different clone 297 
within the hospital environment. Seven out of nine isolates were from ICU patients on 298 
ventilators, so the infection was possibly acquired from colonised ventilators. The swabs 299 
from the ICU environment were taken at the end of the study duration, so we do not have 300 
data on the presence of A. baumannii in the ICU environment prior to the date of sampling. A. 301 
baumannii was able to colonise ventilators, beds and surfaces of the ICU in the current study, 302 
as well as being asymptomatically carried by a healthcare worker, therefore indicating the 303 
urgent need for strict infection control practices in hospitals to control the spread of MDR 304 
organisms. 305 
Conclusion 306 
Two distinct lineages with multiple sub-lineages of strains were present in a 4-month 307 
outbreak of A. baumannii in Tanta University Hospitals (TUH) in Egypt. IC2 was 308 
predominant in addition to a few strains within IC1. Given the short duration of the study, the 309 
degree of heterogeneity is very rare suggesting the circulation of several strains 310 
simultaneously in the hospital environment. The very high rate of carbapenem resistance is 311 
alarming, and is mainly mediated by the presence of OXA-23, NDM and VIM 312 
carbapenemases. The fact that TUH is a regional tertiary referral hospital may explain the 313 
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heterogeneity as clones probably have been brought in to the hospital environment by the 314 
patients possibly from other healthcare facilities, or from the community. Our study sheds 315 
light on the great importance of addressing the molecular epidemiology of A. baumannii 316 
infections. A growing concern of this pathogen is the diverse clonality, the ability to develop 317 
MDR, and the dissemination of the resistance determinants and their related genetic mobile 318 
elements through horizontal gene transfer. Further research is underway to accurately 319 
characterise the genetic vehicles of carbapenem resistance to help understand the nature of 320 
this pathogen in North Africa and the Middle East.  321 
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Table I: Summary of isolate information 461 
Isolate 
Number 
(TN) 
Date of 
admission 
to hospital 
Location of 
Patient 
Type of 
Culture 
Date of 
culture 
Co-morbidities Mode of 
acquisition of 
infection 
Imipenem Meropenem Oxa-51-
like 
OXA-
carbapenemase 
Acquired 
carbapenemase 
Sequence 
Type 
11 13/3/2015 Inpatient BAL 13/3/2015 Immunosuppression Nosocomial S S OXA-
424 
  
ST1291 
30 04/04/2015 ICU BAL 04/04/2015 Haematological 
Malignancy 
Nosocomial R R OXA-65 
 
NDM-1 ST499 
38 17/4/2015 ICU sputum 17/4/2015 Liver Disease Nosocomial R R OXA-66 OXA-23 
 
ST1289 
40 22/4/2015 ICU BAL 22/4/2015 Other Nosocomial R R OXA-66 OXA-23 
 
ST368 
41 23/4/2015 ICU Urine 23/4/2015 Other Nosocomial R R OXA-66 
 
VIM-2 ST1293 
42 26/4/2015 Inpatient Pus 26/4/2015 Diabetes Nosocomial R R OXA-66 OXA-23 NDM-1 ST1294 
44 26/4/2015 ICU BAL 26/4/2015 Other Nosocomial R R OXA-66 OXA-23 
 
ST1295 
46 01/05/2015 ICU BAL 01/05/2015 Other Nosocomial R R OXA-66 OXA-23 
 
unidentified 
49 02/05/2015 Outpatient Pus 02/05/2015 Diabetes Community 
acquired 
I R OXA-66 OXA-23 
 
ST455 
15' 06/05/2015 ICU sputum 06/05/2015 Immunosuppression Nosocomial R R OXA-66 OXA-23 
 
ST195 
25' 09/05/2015 ICU sputum 09/05/2015 Immunosuppression Nosocomial R R OXA-66 
 
NDM-1 ST1296 
52' 12/05/2015 ICU BAL 12/05/2015 Other Nosocomial R R OXA-66 OXA-23 
 
unidentified 
62 13/5/2015 ICU sputum 13/5/2015 Other Nosocomial R R OXA-66 OXA-23 NDM-1 ST1297 
66 14/5/2015 ICU sputum 14/5/2015 Other Nosocomial R R OXA-66 
  
unidentified 
4 03/03/2015 Inpatient BAL 03/03/2015 Other Nosocomial R R OXA-66 
  
unidentified 
7 03/08/2015 Inpatient BAL 08/03/2015 Immunosuppression Nosocomial S S OXA-66 
  
ST425 
22 
 
8 10/03/2015 ICU BAL 10/03/2015 Immunosuppression Nosocomial R R OXA-66 OXA-23 
 
ST1289 
10 13/3/2015 ICU BAL 13/3/2015 Immunosuppression Nosocomial S S OXA-66 
  
ST1290 
12 14/3/2015 Inpatient sputum 14/3/2015 Immunosuppression Nosocomial R R OXA-66 
  
unidentified 
14 16/3/2015 ICU BAL 16/3/2015 Immunosuppression Nosocomial R R OXA-66 OXA-23 
 
ST1292 
39 18/4/2015 ICU Pus 18/4/2015 Other Nosocomial R R OXA-66 OXA-23 
 
ST1289 
43 26/4/2015 ICU BAL 26/4/2015 Other Nosocomial R R OXA-66 OXA-23 NDM-1 ST368 
48 01/05/2015 ICU sputum 01/05/2015 Other Nosocomial R R OXA-66 OXA-23 VIM-2 unidentified 
50 02/05/2015 ICU BAL 02/05/2015 Solid Malignancy Nosocomial R R OXA-66 OXA-23 
 
ST1289 
136 23/5/2015 ICU sputum 23/5/2015 Diabetes Nosocomial R R OXA-66 
 
VIM-2 ST1296 
139 26/5/2015 ICU sputum 26/5/2015 Other Nosocomial R R OXA-66 
 
NDM-1 unidentified 
230 27/5/2015 ICU sputum 27/5/2015 Other Nosocomial R R OXA-66 OXA-23 
 
ST1298 
128 28/5/2015 ICU sputum 28/5/2015 Liver Disease Nosocomial R R OXA-66 
 
NDM-1 ST848 
228 30/5/2015 ICU sputum 30/5/2015 Other Nosocomial R R OXA-66 
 
NDM-1 unidentified 
20 22/3/2015 ICU BAL 22/3/2015 Immunosuppression Nosocomial S S OXA-68 
  
ST391 
1 03/03/2015 Inpatient BAL 03/03/2015 Diabetes Nosocomial I I OXA-69 OXA-23 
 
ST231 
13 15/3/2015 ICU BAL 15/3/2015 Immunosuppression Nosocomial R R OXA-69 OXA-23 
 
ST231 
18 19/3/2015 ICU BAL 19/3/2015 Immunosuppression Nosocomial I I OXA-69 OXA-23 
 
ST231 
24 28/3/2015 Outpatient sputum 28/3/2015 Other Community 
acquired 
R R OXA-69 OXA-23 
 
ST231 
26 04/02/2015 ICU BAL 02/04/2015 Other Nosocomial R R OXA-69 OXA-23 
 
ST231 
32 04/06/2015 Inpatient BAL 06/04/2015 Liver Disease Nosocomial R R OXA-69 
 
NDM-1 ST441 
33 04/10/2015 ICU BAL 10/04/2015 Immunosuppression Nosocomial R R OXA-69 
 
NDM-1 ST441 
23 
 
2 03/03/2015 ICU BAL 03/03/2015 Immunosuppression Nosocomial R R OXA-70 
  
unidentified 
3 03/03/2015 Inpatient Urine 03/03/2015 Renal Disease Nosocomial R R OXA-88 
 
NDM-2 unidentified 
22 26/3/2015 ICU BAL 26/3/2015 Solid Malignancy Nosocomial S S OXA-94 
 
NDM-1 ST1078 
34 04/11/2015 ICU BAL 11/04/2015 Immunosuppression Nosocomial R R OXA-94 
 
NDM-1 ST1078 
83 19/5/2015 ICU sputum 19/5/2015 Other Nosocomial I R OXA-94 OXA-23 NDM-1 ST1078 
91 30/5/2015 ICU BAL 30/5/2015 Other Nosocomial R R OXA-94 
 
NDM-1 ST1078 
14' 01/06/2015 ICU BAL 01/06/2015 Other Nosocomial I I OXA-94 
  
ST1078 
35 13/4/2015 ICU Blood 13/4/2015 Liver Disease Nosocomial S S OXA-98 
  
ST931 
ICU environmental swabs 
241 02/06/2015 ICU ventilator 5  02/06/2015 
  
R R OXA-66 OXA-23 
 
unidentified 
242 02/06/2015 ICU floor 02/06/2015 
  
R R OXA-66 OXA-23 
 
unidentified 
238 02/06/2015 ICU ventilator 4  02/06/2015 
  
R R OXA-66 OXA-23 VIM-1 unidentified 
235 02/06/2015 ICU wall swab 02/06/2015 
  
R R OXA-66 OXA-23 
 
ST1114 
236 02/06/2015 ICU ventilator 2  02/06/2015 
  
R R OXA-94 
 
NDM-1 ST1078 
237 02/06/2015 ICU ventilator 3 02/06/2015 
  
R R OXA-94 
 
NDM-1 ST1078 
234 02/06/2015 ICU staff hands 02/06/2015 
  
I I OXA-69 OXA-23 
 
ST231 
239 02/06/2015 ICU bed 1 02/06/2015 
  
I I OXA-69 OXA-23 
 
unidentified 
240 02/06/2015 ICU bed 2 02/06/2015 
  
R R OXA-69 
  
unidentified 
R: Resistant, S: Sensitive, I: Intermediate. 
Unidentified ST due to inability to amplify gpi and/or ghbB loci 
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Table II: Analysis of risk factors predisposing to 15-day mortality in patients infected with A. 463 
baumannii 464 
 465 
 466 
*Results are presented as mean ± standard deviation or n (%). 467 
  468 
Parameters 
Outcome* Univariate 
analysis 
p-value 
Multivariate analysis 
Survival 
n = 25 
Number (%) 
Mortality 
n = 29 
Number (%) 
Odds ratio (95% 
confidence interval CI) p-value 
Age (years) 41±12.8 44.7±13.2 0.71 0.67 (0.52-1.42) 0.44 
male 15 (32.6) 9 (31) 0.96 0.72 (0.95-1.03) 0.59 
-Co-morbidities:  
Diabetes 4 (16) 0 (0) 1.00   
Haematological malignancy 1 (4) 0 (0) 0.85   
Immune suppression  16 (64) 20 (70) 0.006 1.95(1.02-3.3) 0.034 
Liver Disease  3 (12) 1 (3.4) 0.922   
Renal Disease 0 (0) 1 (3.4) 0.423   
Solid Malignancy 8 (32) 2 (6.9) 0.05 0.91 (0.52-1.2) 0.32 
Burns 18 (72) 1 (3.4) 0.36   
-Focus of infection  
Ventilator-associated pneumonia 11 (44) 21 (72.4) 0.003 2.85 (1.3-5.15) 0.017 
Intra-abdominal infections 2 (8) 3 (10.3) 0.73   
Central venous catheter 5 (20) 1 (3.4) 0.76   
UTI infections 3 (12) 0 (0 ) 0.91   
Post-surgical wound infection 3 (12) 0 (0) 1   
-Longer stay in ICU 7 (28) 25 (86.2) 0.002 3.71 (0.35-4.36) 0.052 
-Mode of acquision of infection  
Community 5 (20) 0 (0) 0.81   
nosocomial 25 (100) 29 (100)  0.001 3.92 (0.83-7.65) 0.021 
-Recurrent Gram-negative 
infections 
 
A. baumannii 9(36) 12(41.4) 0.02 1.38(1.25-2.11) 0.043 
Klebsiella pneumoniae 3(12) 1(3.4) 0.901   
E. coli 7(28) 1(3.4) 0.524   
Pseudomonas  aeruginosa 2(8) 1(3.4) 0.82   
25 
 
Figure 1: Maximum Likelihood Phylogeny (PhyML) of concatenated Sequence Types (STs)    469 
   identified in the study 470 
 471 
 472 
Two separate lineages were identified in the study, with multiple sub-lineages of closely related isolates.  473 
Lineage 1, was less diverse, and all had OXA-66 as their intrinsice OXA-51-like. Whereas lineage 2 was more 474 
diverse and contained different OXA-51-like variants. OXA-23, NDM and VIM carbapenemases were 475 
distributed across both lineages, although OXA-23 occurred more frequently in lineage 1, and NDM-1 was more 476 
frequently found in isolates in lineage 2.  477 
The associated metadata of the STs are added using Phandango (27) 478 
 479 
